ASX:IMMPharmaceuticals, Biotechnology & Life SciencesBiotechnology
Immutep Ltd
$0.048
$0.003 (5.88%)
Day Range
$0.048 – $0.051
52 Week Range
$0.028 – $0.470
Volume
16.60M
Avg Volume (10D)
14.08M
Market Cap
$70.74M
Price Chart
Market Statistics
Open$0.051
Previous Close$0.051
Day High$0.051
Day Low$0.048
52 Week High$0.470
52 Week Low$0.028
Valuation
Market Cap70.74M
Shares Outstanding1.47B
Price to Book0.76
Trading Activity
Volume16.60M
Value Traded821.70K
Bid$0.048 × 1,146,573
Ask$0.050 × 213,150
Performance
1 Day-1.92%
5 Day4.08%
13 Week10.87%
52 Week-78.75%
YTD-87.71%
Technical Indicators
RSI (14)38.20
50-Day SMA$0.057
200-Day SMA$0.231
Latest News
Biotechnology
Immutep Granted FDA Orphan Drug Designation for Efti in Soft Tissue Sarcoma
Immutep wins FDA Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma, boosting exclusivity and regulatory support as TACTI-004 winds down.
Hot Topics
Weekly Wrap: Shares fall another 2.6% for the week as conflict worsens
ASX 200 slides 2.6% this week to 8,617 as Iran-Israel conflict lifts oil above $100; NST and SYR plunge, while EOS soars on a Middle East contract.
Biotechnology
Immutep Discontinues TACTI-004 Phase III Trial Due to Futility
Immutep halts TACTI-004 Phase III in first-line NSCLC due to futility; shares resume trading as cash runway extends beyond Q2 CY2027.
Biotechnology
Immutep TACTI-004 NSCLC Trial At 50% Enrolment, Paving Way for Futility Analysis
Immutep (ASX: IMM) has achieved a significant milestone, announcing 50% patient enrolment in its global Phase III TACTI-004 trial for first-line non-small ce